/clinical/,/clinical/cckm-tools/,/clinical/cckm-tools/content/,/clinical/cckm-tools/content/beacon-protocols/,/clinical/cckm-tools/content/beacon-protocols/supportive-care/,

/clinical/cckm-tools/content/beacon-protocols/supportive-care/name-122976-en.cckm

201711331

page

100

UWHC,UWMF,

Tools,

Clinical Hub,UW Health Clinical Tool Search,UW Health Clinical Tool Search,Beacon Protocols,Supportive Care

CSC SC Zoledronic Acid (Zometa) 4 mg Monthly X 12 Months Ver 11-20-17 (HL 1881)

CSC SC Zoledronic Acid (Zometa) 4 mg Monthly X 12 Months Ver 11-20-17 (HL 1881) - Clinical Hub, UW Health Clinical Tool Search, UW Health Clinical Tool Search, Beacon Protocols, Supportive Care


CSC SC ZOLEDRONIC ACID (ZOMETA) 4 MG MONTHLY X 12 MONTHS VER: 11-20-17 –  Properties
Cycle 1 –  11/22/2017 through 12/19/2017 (28 days), Planned
Day 1, Cycle 1 –  Planned for 11/22/2017
Treatment Conditions
Treatment Condition A
Dose in normal renal function = zoledronic acid 4 mg. Dose modification may be required for renal dysfunction
(Creatinine Clearance less than 60 mL/min).
Hydration
sodium chloride 0.9 % infusion
at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Supportive Care Medications
zoledronic acid (ZOMETA) 4 MG/100ML bag 4 mg
4 mg, Intravenous, ONCE, 1 dose Starting when released, Administer over 15-30 Minutes
Administer over 15 to 30 minutes.
Cycle 2 –  12/20/2017 through 1/16/2018 (28 days), Planned
Day 1, Cycle 2 –  Planned for 12/20/2017
Treatment Conditions
Treatment Condition A
Dose in normal renal function = zoledronic acid 4 mg. Dose modification may be required for renal dysfunction
(Creatinine Clearance less than 60 mL/min).
Hydration
sodium chloride 0.9 % infusion
at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Supportive Care Medications
zoledronic acid (ZOMETA) 4 MG/100ML bag 4 mg
4 mg, Intravenous, ONCE, 1 dose Starting when released, Administer over 15-30 Minutes
Administer over 15 to 30 minutes.
Cycle 3 –  1/17/2018 through 2/13/2018 (28 days), Planned
Day 1, Cycle 3 –  Planned for 1/17/2018
Treatment Conditions
Treatment Condition A
Dose in normal renal function = zoledronic acid 4 mg. Dose modification may be required for renal dysfunction
(Creatinine Clearance less than 60 mL/min).
Hydration
sodium chloride 0.9 % infusion
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
ZZtestonc,Andrew [2428787]
11/22/2017 1:10:00 PM Page 1 of 3
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org

at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Supportive Care Medications
zoledronic acid (ZOMETA) 4 MG/100ML bag 4 mg
4 mg, Intravenous, ONCE, 1 dose Starting when released, Administer over 15-30 Minutes
Administer over 15 to 30 minutes.
Cycle 4 –  2/14/2018 through 3/13/2018 (28 days), Planned
Day 1, Cycle 4 –  Planned for 2/14/2018
Treatment Conditions
Treatment Condition A
Dose in normal renal function = zoledronic acid 4 mg. Dose modification may be required for renal dysfunction
(Creatinine Clearance less than 60 mL/min).
Hydration
sodium chloride 0.9 % infusion
at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Supportive Care Medications
zoledronic acid (ZOMETA) 4 MG/100ML bag 4 mg
4 mg, Intravenous, ONCE, 1 dose Starting when released, Administer over 15-30 Minutes
Administer over 15 to 30 minutes.
Cycle 5 –  3/14/2018 through 4/10/2018 (28 days), Planned
Day 1, Cycle 5 –  Planned for 3/14/2018
Treatment Conditions
Treatment Condition A
Dose in normal renal function = zoledronic acid 4 mg. Dose modification may be required for renal dysfunction
(Creatinine Clearance less than 60 mL/min).
Hydration
sodium chloride 0.9 % infusion
at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Supportive Care Medications
zoledronic acid (ZOMETA) 4 MG/100ML bag 4 mg
4 mg, Intravenous, ONCE, 1 dose Starting when released, Administer over 15-30 Minutes
Administer over 15 to 30 minutes.
Cycle 6 –  4/11/2018 through 5/8/2018 (28 days), Planned
Day 1, Cycle 6 –  Planned for 4/11/2018
Treatment Conditions
Treatment Condition A
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
ZZtestonc,Andrew [2428787]
11/22/2017 1:10:00 PM Page 2 of 3
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised:
 
11/2017CCKM@uwhealth.org

Dose in normal renal function = zoledronic acid 4 mg. Dose modification may be required for renal
dysfunction (Creatinine Clearance less than 60 mL/min).
Hydration
sodium chloride 0.9 % infusion
at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Supportive Care Medications
zoledronic acid (ZOMETA) 4 MG/100ML bag 4 mg
4 mg, Intravenous, ONCE, 1 dose Starting when released, Administer over 15-30 Minutes
Administer over 15 to 30 minutes.
Actions
Actions
Actions
Actions
Actions
ZZtestonc,Andrew [2428787]
11/22/2017 1:10:00 PM Page 3 of 3
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised:
 
11/2017CCKM@uwhealth.org